GH Research (NASDAQ:GHRS) Reaches New 12-Month High Following Earnings Beat
GH Research (NASDAQ:GHRS) recently hit a new 52-week high after reporting quarterly earnings that surpassed analyst expectations, with an EPS of negative $0.23 against an estimated negative $0.29. The clinical-stage biotech, focusing on psychedelic-inspired treatments for neuropsychiatric disorders, maintains a "Moderate Buy" consensus rating …